000908.SZ SHZ
Hunan Jingfeng Pharmaceutical Co.,Ltd.
1W: -1.8%
1M: -7.1%
3M: -4.2%
YTD: -10.2%
1Y: -0.2%
3Y: +133.1%
5Y: +18.1%
¥5.99 ($0.89)
+0.04 (+0.67%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$416M
-36.7% ▼
5Y CAGR: -20.9%
Gross Profit
$261M
-44.6% ▼
5Y CAGR: -20.2%
Operating Income
$204M
+217.9% ▲
Net Income
$152M
+170.8% ▲
EPS (Diluted)
$0.17
+170.8% ▲
EBITDA
$234M
+361.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $878M | $811M | $841M | $657M | $416M |
| YoY Growth | -34.7% | -7.6% | +3.6% | -21.9% | -36.7% |
| Cost of Revenue | $318M | $308M | $200M | $186M | $155M |
| Gross Profit | $560M | $503M | $641M | $471M | $261M |
| Gross Margin | 63.7% | 62.0% | 76.2% | 71.8% | 62.8% |
| R&D Expenses | $253M | $39M | $36M | $53M | $13M |
| SG&A Expenses | $679M | $593M | $481M | $413M | $250M |
| Operating Expenses | $1.1B | $761M | $624M | $644M | $57M |
| Operating Income | -$514M | -$21M | $14M | -$173M | $204M |
| Operating Margin | -58.6% | -2.6% | 1.7% | -26.3% | 49.0% |
| Interest Expense | $108M | $86M | $52M | $40M | $40M |
| Income Before Tax | -$1.2B | -$155M | -$91M | -$174M | $165M |
| Tax Expense | $3M | $46M | $10M | $33M | $5M |
| Net Income | -$1.2B | -$202M | -$101M | -$215M | $152M |
| Net Margin | -131.6% | -24.9% | -12.0% | -32.8% | 36.6% |
| EPS (Diluted) | $-1.31 | $-0.23 | $-0.11 | $-0.24 | $0.17 |
| EBITDA | -$925M | $58M | $22M | -$89M | $234M |
| Shares Outstanding | 880M | 880M | 880M | 880M | 880M |